MedinCell

[Not Yet Scheduled]
MedinCell is a clinical stage pharmaceutical company developing long acting injectables based on BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. Independently and in partnership with other pharma companies or NGOs, MedinCell develops a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action and ease of use.
Ticker:
MEDCL
Exchange:
Euronext
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2002
Main Therapeutic Focus:
Lead Product in Development:
Long-acting risperidone for the treatment of Schizophrenia
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Partnering Manager, US
MedinCell